Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) kicked off on Tuesday, down -6.13% from the previous trading day, before settling in for the closing price of $41.12. Over the past 52 weeks, KNSA has traded in a range of $17.82-$44.42.
Healthcare Sector giant saw their annual sales surged by 27.38% over the last five years. While this was happening, its average annual earnings per share was recorded 264.31%. With a float of $43.33 million, this company’s outstanding shares have now reached $44.79 million.
Kiniksa Pharmaceuticals International Plc (KNSA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Kiniksa Pharmaceuticals International Plc is 42.83%, while institutional ownership is 54.79%. The most recent insider transaction that took place on Jan 08 ’26, was worth 502,680. In this transaction CHIEF FINANCIAL OFFICER of this company sold 12,000 shares at a rate of $41.89, taking the stock ownership to the 19,086 shares. Before that another transaction happened on Dec 15 ’25, when Company’s Director sold 20,129 for $41.51, making the entire transaction worth $835,555. This insider now owns 12,546 shares in total.
Kiniksa Pharmaceuticals International Plc (KNSA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.12 earnings per share (EPS), lower than consensus estimate (set at 0.13) by -0.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 264.31% per share during the next fiscal year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
Take a look at Kiniksa Pharmaceuticals International Plc’s (KNSA) current performance indicators. Last quarter, stock had a quick ratio of 3.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.89. Likewise, its price to free cash flow for the trailing twelve months is 28.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.45, a number that is poised to hit 0.35 in the next quarter and is forecasted to reach 1.62 in one year’s time.
